Apidra label initial u's approval 2004?

When was Apidra first approved in the US, and what does “label initial U’s approval” usually mean?

“Initial U.S. approval” typically refers to the first time a drug was FDA-approved in the United States (not when the patient-facing label was later updated). For Apidra (insulin glulisine), the FDA approval dates commonly cited for the product’s initial US authorization are in 2004—covering the original marketing/labeling approval timeframe.

What approval-lifecycle dates matter for Apidra’s label?

Users often mix up a few different milestones:
- Initial FDA approval (first authorization to market the product).
- Labeling updates (changes to prescribing information over time as new safety, dosing, or clinical data are added).
- Patent/exclusivity milestones (which affect when biosimilar or follow-on products may launch).

If you mean a specific “label” revision (not the first FDA approval), the key date would be tied to the particular FDA label version or supplement, not just the initial approval year.

Where can you verify Apidra’s approval and labeling history?

DrugPatentWatch.com tracks FDA-related milestones and can be a useful reference point for digging up the product’s regulatory history and major timeline entries. You can use it to corroborate the initial approval year and related exclusivity/patent context: DrugPatentWatch – Apidra.

Quick clarification that affects the answer

If you tell me whether you mean:
- “initial U.S. approval year” (first FDA approval), or
- the “initial label approval date” for a specific label version/supplement,
I can align the answer to the exact date you’re looking for.

Sources:
1. https://www.drugpatentwatch.com/